Pi Health is committed to empowering life sciences companies
to develop medicines faster and reach diverse patient
populations
Leadership
Meet the team that's transforming
capabilities for life sciences companies and
revolutionizing patient access to innovative
medicines and clinical trials
CPO (Chief Product Officer & Head of Clinical Research)
Chao Liu, PhD
Chief Financial Officer
Alex Morozov, MD, PhD
Chief Medical Officer
Hayes Kim
Chief Development Officer
Board of Directors
Brenton Fargnoli, MD
Board Director
General Partner, AlleyCorp
Vishal Vasishth
Board Observer
Co-Founder and Managing Director, Obvious Ventures
Rohan Ganesh
Board Director
Partner, Obvious Ventures
Michael Schoen
Board Director
Strategic Advisor and Special Assistant to CEO,
BeiGene
Geoff Kim, MD
Board Director
Co-Founder, CEO of Pi Health
Bobby Reddy, MD
Board Director
Co-Founder, COO of Pi Health
Kevin Ryan
Board Advisor
Founder & CEO, AlleyCorp
Request Demo
Your request has been processed.
Geoff Kim, MD
Co-Founder & CEO
Dr. Geoffrey Kim is the co-founder and Chief Executive Officer of
Pi Health, a healthcare technology company launched in 2021 whose
mission is to drive innovation to enable patients all over the
world to have equal access to the highest quality of care and
research. He has over 25 years of experience in oncology drug
development, regulation, and precision medicine.
As Vice President of Applied Innovation at BeiGene, Geoff
established an innovative team focused on increasing patient
access to clinical trials and novel cancer therapies. His group
pioneered methodologies to integrate diverse datasets and drive
pipeline advancement through data analysis and strategic
development, while simultaneously laying the groundwork for the
establishment of Pi Health through the invention of the FICS
technology platform.
Prior to his role at BeiGene, Geoff served as Vice President of
Oncology Regulatory Science and Strategy at AstraZeneca. He led
the regulatory function and shaped regulatory strategies for
oncology treatments in a complex, evolving landscape, leading to
the approvals of acalabrutinib in CLL and trastuzumab-deruxtecan
in metastatic breast cancer. Previously, as Vice President of
Strategic Combinations, he defined development and
commercialization approaches for immuno-oncology combinations,
external partnerships, and women’s cancers, including the
strategic oversight of IO-based combination such as the
combination of durvalumab and olaparib in multiple solid tumors.
Earlier in his career, Geoff played a pivotal role in oncology
regulation at the U.S. Food and Drug Administration (FDA). As
Deputy Director of the Oncology Center of Excellence, he helped
launched the OCE under the provisions of the 21st Century Cures
Act and laid the framework for the unified review of drugs,
devices, and biologics that are intended to cure, treat, and
prevent cancer. Geoff was also director of the Division of
Oncology Products 1 in the Office of Hematology Oncology Products,
where he oversaw the evaluation and regulation of oncology drug
products for breast, genitourinary and gynecologic cancers and
approved practice changing medicines such as CDK4/6 inhibitors for
breast cancers, PARP inhibitors for ovarian cancers, and
immunotherapy for genitourinary malignancies. He was also involved
with numerous cross-functional working groups, developing policies
pertaining to in-vitro companion diagnostics, combination
products, and therapy dose optimization strategies for cancer
medicines.
Dr. Kim completed his medical oncology fellowship at the National
Cancer Institute (NCI) where he was active in both laboratory and
clinical research in molecular signaling and ovarian cancer. He
received his medical degree from New York Medical College and
completed his residency in internal medicine at the Montefiore
Medical Center.
Bobby Reddy, MD
Co-Founder & CEO
Dr. Bobby Reddy, MD is the Chief Operating Officer and Co-Founder
of Pi Health. At Pi Health, he leads global operations, business
development, and commercial activities with the mission of driving
equal access to innovative medicines and clinical trials for
patients around the world. Previously, he served in leadership
positions at BeiGene and AstraZeneca. At BeiGene, he was Executive
Director of Applied Innovation, a technology incubator in the
Office of the CEO, which developed novel technologies to improve
R&D and commercial capabilities. In this role, Dr. Reddy was the
co-inventor of multiple patented technology applications which
have successfully undergone enterprise adoption. He also built and
managed multidisciplinary, global teams who led strategy, business
development, global operations, and legal activities to drive
development, implementation and growth of incubated technologies
and companies. At AstraZeneca, Dr. Reddy was Head of Oncology
Regulatory Science and Innovation, where he was a member of the
global Oncology Regulatory Science and Strategy leadership team.
Previous to his roles in pharma and biotech, Dr. Reddy was faculty
of Harvard Medical School and a physician scientist and clinical
dermatologist at Massachusetts General Hospital. His research
focused on investigating the role of genetic and immunologic
factors in melanoma development and progression, along with the
development of novel therapeutic strategies. He is also an alumnus
of the Howard Hughes Medical Institute – National Institutes of
Health Research Scholars Program, through which he conducted
research at the National Cancer Institute. He completed an
Internal Medicine internship at Brigham and Women’s Hospital,
during which he was given the Dunne Award for Humanism in Medicine
by Harvard Medical School. He subsequently completed a Dermatology
residency at Columbia University Medical Center, where he served
as a Chief Resident during his final year of training. After
residency, he completed a Melanoma Fellowship at Massachusetts
General Hospital/Harvard Medical School. He obtained his M.D. with
Alpha Omega Alpha honors from Rutgers–New Jersey Medical School.
Dr. Reddy is a board-certified dermatologist and maintains an
active clinical practice caring for patients at Massachusetts
General Hospital, where he also teaches and mentors medical
students and trainees.
Rajuli Lall
CPO (Chief Product Officer & Head of Clinical Research)
Rajuli Lall is a visionary leader and the Chief Product Officer
and Head of Clinical Research at Pi Health. Her strategic acumen
and extensive expertise in clinical development and operations
have made her an instrumental force within the organization and
the development of the FICS® software platform. With an
illustrious career that spans leading pharmaceutical companies,
innovative biotech firms, and academia, Rajuli has carved a niche
in the realm of oncology drug and product development.
She is recognized for her adeptness in steering global clinical
trials, managing cohesive cross-functional teams, and providing
meticulous oversight of clinical operations. As a research
scientist, Rajuli specialized in the study of Molecular Medicine
and Radiation Biophysics, with a particular emphasis on the
biological underpinnings of cancer. Her contributions are a
testament to her commitment to advancing medical research and
innovation.
Rajuli Lall's profound knowledge and pioneering spirit are central
to Pi Health's mission, enabling the company to transform clinical
trials and healthcare technology across the globe.
Chao Liu, PhD
Chief Financial Officer
Dr. Chao Liu, as the Chief Financial Officer and a Founding Member
of Pi Health since September 2021, plays a critical role in
steering the company's strategic financial direction. Based in the
Washington DC-Baltimore area, his expertise is central to Pi
Health's mission of revolutionizing clinical research globally
through cutting-edge technology.
Before his current role at Pi Health, Dr. Liu served as Senior
Director of Applied Innovation Quantitative Solutions at BeiGene.
His impactful work included creating and delivering tailored
analytic solutions, performing market assessments and real-time
valuations, implementing innovative technology in oncology
therapeutic development.
Prior to BeiGene, Liu was part of the Food and Drug Administration
(FDA) from September 2014 to December 2019. He started as a
Reviewer in Clinical Pharmacology/Pharmacometrics and later became
a Team Leader in the same division. His focus areas included
oncology, hematology, infectious diseases, cardiovascular, and
renal diseases. At the FDA, Dr. Liu was responsible for overseeing
high-quality and timely reviews of NDA and IND submissions,
supervising and mentoring review teams, and leading research
projects in regulatory sciences. In addition, he led or
participated in the drafting and publication of multiple FDA
guidance for industry.
Dr. Liu's journey through these diverse roles reflects a deep
commitment to advancing the integration of financial strategy with
healthcare innovation. His expertise in quantitative analysis and
regulatory sciences, coupled with his financial acumen, positions
him as a key driver in Pi Health's pursuit of transforming
clinical research infrastructure on a global scale.
Alex Morozov, MD, PhD
Chief Medical Officer
Alex Morozov joins Pi Health as Chief Medical Officer.
Alex is a drug developer and digital health leader with a passion
for improving patient outcomes around the world through innovative
therapies and technologies.
In his industry career, Alex has overseen hundreds of clinical
trials spanning early and late phase development in oncology at
several major pharmaceutical companies, helping bring several new
therapies to cancer patients including Bavencio, Lorbrena,
Cyramza, Jakavi, Opdivo/Yervoy and Cabometyx.
He spearheaded multiple innovations aimed at improving quality,
efficiency and speed of drug development. While at BMS, he built
and led the first Digital Health team, overseeing a portfolio of
digital products across cardiovascular, immunology, oncology,
hematology, and cell therapy areas.
Alex has a Bachelor's of Science degree from Massachusetts
Institute of Technology and MD-PhD from Albert Einstein College of
Medicine. He completed his internal medicine residency at Columbia
Presbyterian Medical Center, followed by a medical oncology
fellowship at Memorial Sloan-Kettering Cancer Center. After
joining industry, Alex served as a volunteer Attending Physician
in the Division of Oncology, New York Hospital - Weill Cornell
Medical Center.
Alex lives in New York City with his wife, two children and a
poodle.
Hayes Kim
Chief Development Officer
Hayes Kim, as the Chief Development Officer of Pi Health since
April 2024, is a pivotal figure in advancing the company's mission
in health technology and clinical research. Based in the Los
Angeles Metropolitan Area, his expertise is crucial in Pi Health's
commitment to revolutionizing global access to innovative
medicines and clinical trials, ensuring patients worldwide have
equal access to the highest quality of care and research.
In his role at Pi Health, Kim is responsible for aligning the
product vision with technical capabilities, driving the execution
of the product roadmap, and establishing a model for customer
obsession. His work focuses on developing a comprehensive,
end-to-end technology platform that streamlines clinical trials,
reduces costs, and improves patient outcomes.
Prior to joining Pi Health, Kim served as the SVP of Engineering
at AuditBoard from July 2019 to July 2023. At AuditBoard, he led
the growth and scaling of their next-generation GRC SaaS Platform,
managing product engineering, infrastructure, information
security, and IT organizations during a critical phase of company
growth. During his tenure, platform revenue grew from $17M to
$170M+. In July 2024, AuditBoard exited via acquisition to HG for
over $3B.
Hayes' career includes a significant tenure at Verizon Digital
Media Services, where he held the position of Vice President of
Engineering from January 2016 to July 2019. In this role, he led
product and engineering teams responsible for building EdgeCast,
the next-generation Edge network, the 2nd largest of it's kind in
the world.
Before his time at Verizon, Kim held various roles in product
management and development at companies such as the Rubicon
Project, Experian Marketing Services, and Lunch.com. These
experiences contributed to his broad knowledge across SaaS, PaaS,
and IaaS domains in areas including edge computing, content
delivery, big data, mobile technology, digital video, online
advertising, e-commerce, and social media.
Throughout his career, Kim has authored a total of six patents,
several of which have helped define industry best practices for
online video, content delivery, and web security. His ability to
dive deep technically while also operating broadly at a high level
has been a hallmark of his professional journey.
Hayes' educational background includes a B.A. from UCLA in
Economics and Computing. Since March 2018, he has been an active
member of the LA CTO Forum, contributing to the vibrant tech
community in Los Angeles.
Hayes Kim's career trajectory showcases his exceptional ability to
blend deep technical knowledge with strategic business acumen,
making him an integral part of Pi Health's leadership in driving
technological innovation in health technology and clinical
research.
Brenton Fargnoli, MD
Board Director
General Partner, AlleyCorp
Brenton is a General Partner leading the Healthcare team at
AlleyCorp, where he leads investments and incubations across
digital health with a particular focus on value-based care and
physician entrepreneurship. Prior to AlleyCorp, Brenton was an
executive at Flatiron Health (acquired by Roche), where he built
its value-based care business from the ground up and was
instrumental in the launch of OneOncology (acquired by
AmerisourceBergen). He worked previously at J.P. Morgan and Blue
Cross & Blue Shield. An avid supporter of the New York healthcare
ecosystem, Brenton serves on the boards of Fund for Public Health
NYC and Digital Health New York.
Board-certified in Internal Medicine, Brenton previously practiced
at Memorial Sloan Kettering and completed residency at Harvard’s
Brigham and Women’s Hospital. He graduated summa cum laude from
the University of Pennsylvania, earning an MD from the University
of Pennsylvania School of Medicine and an MBA in Healthcare
Management from the Wharton School.
Vishal Vasishth
Board Observer
Co-Founder and Managing Director, Obvious Ventures
Vishal invests in values-driven founders and companies that
dramatically improve healthcare outcomes, create more
human-centered financial systems, and reimagine consumer services
from the ground up.
He leads Obvious' investments in full-stack healthcare with Virta,
Galileo, and Devoted Health; financial technology startups such as
Hedvig, One, Corvus, and Openly; and purpose-led consumer services
like Good Eggs and Block Renovation.
Before co-founding Obvious, Vishal was the founding partner of
Indian-based fund SONG Investment Advisors. He also served as a
senior executive at Steve Case’s Revolution, LLC. Prior to his
career as an investor, Vishal spent a decade at outdoor gear and
apparel retailer Patagonia, in roles ranging from product manager
to Chief Strategy Officer. He was selected as a Henry Crown Fellow
of the Aspen Institute and a Next Generation Fellow of the
American Assembly, both recognizing value-based leadership. Vishal
earned a B. Tech degree in India, an MS from North Carolina State
University, and an MBA from UCLA's Anderson School of Management.
Rohan Ganesh
Board Director
Partner, Obvious Ventures
Rohan invests in mission-driven team building companies that
transform pharma operations and catalyze biological breakthroughs.
Prior to joining Obvious, he led venture investments in biotech,
diagnostics, and healthcare technology companies at Verily Life
Sciences, a Google spinout, and at Northpond Ventures, a
life-sciences focused venture firm. He started his career in
product management roles at CompuGroup Medical, building
electronic medical records, and at Verily, productizing neural
networks for diagnostic applications.
Rohan studied Biological Sciences at the University of Oxford and
earned an MBA from Harvard Business School.
Michael Schoen
Board Director
Strategic Advisor and Special Assistant to CEO, BeiGene
Michael joined BeiGene in 2017 and serves as Strategic Advisor and
Special Assistant to the CEO. In addition, Michael oversees Global
IT, Global Workplace Services, and U.S. Government Affairs. Prior
to that he was Chief of Staff and Special Advisor to the CEO as
well as SVP, Business Operations, overseeing Global HR, Global IT,
Global Workplace Services, and U.S. Corporate Communications. In
all those roles Michael works closely with John V. Oyler and other
senior management to help direct BeiGene's operations and work to
meet its goals.
Before joining BeiGene, Michael was a Managing Director and the
Regional Head of Latin America and Caribbean Debt Capital Markets
and Derivative Solutions for Scotiabank, based in New York. In
this capacity, he was responsible for overseeing the origination
and execution of all debt and derivative transactions from and
within the region. Michael joined Scotiabank in early 2013 after
twelve years in a similar capacity at Credit Suisse. Michael
joined Credit Suisse in 2000 when the bank merged with Donaldson,
Lufkin & Jenrette, where he was a member of the High Yield Capital
Markets group. Prior to that, Michael worked at J.P. Morgan and
Lehman Brothers, respectively, in their Emerging Markets groups.
Michael graduated from the Massachusetts Institute of Technology
with a Bachelor of Science in Management from the Sloan School of
Management. Michael is Chairman of the Board of Directors for
HealthCare Chaplaincy Network, Inc., a leader in the research,
education, and practice of spirituality within health care and
palliative care, as well as . He also serves on the Board of
Trustees of BioNJ, the life sciences trade association for New
Jersey. Michael grew up in Ohio and has long been a supporter of
The Ohio State University's James Cancer Center through Pelotonia,
a cancer fundraising ride. In 2023 he was awarded the Pelotonia
Legacy Award, in part for raising over $1.1M over the past
fourteen years to support cancer research.
Geoff Kim
MD, Board Director
Co-Founder, CEO of Pi Health
Dr. Geoffrey Kim is the co-founder and Chief Executive Officer of
Pi Health, a healthcare technology company launched in 2021 whose
mission is to drive innovation to enable patients all over the
world to have equal access to the highest quality of care and
research. He has over 25 years of experience in oncology drug
development, regulation, and precision medicine.
As Vice President of Applied Innovation at BeiGene, Geoff
established an innovative team focused on increasing patient
access to clinical trials and novel cancer therapies. His group
pioneered methodologies to integrate diverse datasets and drive
pipeline advancement through data analysis and strategic
development, while simultaneously laying the groundwork for the
establishment of Pi Health through the invention of the FICS
technology platform.
Prior to his role at BeiGene, Geoff served as Vice President of
Oncology Regulatory Science and Strategy at AstraZeneca. He led
the regulatory function and shaped regulatory strategies for
oncology treatments in a complex, evolving landscape, leading to
the approvals of acalabrutinib in CLL and trastuzumab-deruxtecan
in metastatic breast cancer. Previously, as Vice President of
Strategic Combinations, he defined development and
commercialization approaches for immuno-oncology combinations,
external partnerships, and women’s cancers, including the
strategic oversight of IO-based combination such as the
combination of durvalumab and olaparib in multiple solid tumors.
Earlier in his career, Geoff played a pivotal role in oncology
regulation at the U.S. Food and Drug Administration (FDA). As
Deputy Director of the Oncology Center of Excellence, he helped
launched the OCE under the provisions of the 21st Century Cures
Act and laid the framework for the unified review of drugs,
devices, and biologics that are intended to cure, treat, and
prevent cancer. Geoff was also director of the Division of
Oncology Products 1 in the Office of Hematology Oncology Products,
where he oversaw the evaluation and regulation of oncology drug
products for breast, genitourinary and gynecologic cancers and
approved practice changing medicines such as CDK4/6 inhibitors for
breast cancers, PARP inhibitors for ovarian cancers, and
immunotherapy for genitourinary malignancies. He was also involved
with numerous cross-functional working groups, developing policies
pertaining to in-vitro companion diagnostics, combination
products, and therapy dose optimization strategies for cancer
medicines.
Dr. Kim completed his medical oncology fellowship at the National
Cancer Institute (NCI) where he was active in both laboratory and
clinical research in molecular signaling and ovarian cancer. He
received his medical degree from New York Medical College and
completed his residency in internal medicine at the Montefiore
Medical Center.
Bobby Reddy
MD, Board Director
Co-Founder, CEO of Pi Health
Dr. Bobby Reddy, MD is the Chief Operating Officer and Co-Founder
of Pi Health. At Pi Health, he leads global operations, business
development, and commercial activities with the mission of driving
equal access to innovative medicines and clinical trials for
patients around the world. Previously, he served in leadership
positions at BeiGene and AstraZeneca. At BeiGene, he was Executive
Director of Applied Innovation, a technology incubator in the
Office of the CEO, which developed novel technologies to improve
R&D and commercial capabilities. In this role, Dr. Reddy was the
co-inventor of multiple patented technology applications which
have successfully undergone enterprise adoption. He also built and
managed multidisciplinary, global teams who led strategy, business
development, global operations, and legal activities to drive
development, implementation and growth of incubated technologies
and companies. At AstraZeneca, Dr. Reddy was Head of Oncology
Regulatory Science and Innovation, where he was a member of the
global Oncology Regulatory Science and Strategy leadership team.
Previous to his roles in pharma and biotech, Dr. Reddy was faculty
of Harvard Medical School and a physician scientist and clinical
dermatologist at Massachusetts General Hospital. His research
focused on investigating the role of genetic and immunologic
factors in melanoma development and progression, along with the
development of novel therapeutic strategies. He is also an alumnus
of the Howard Hughes Medical Institute – National Institutes of
Health Research Scholars Program, through which he conducted
research at the National Cancer Institute. He completed an
Internal Medicine internship at Brigham and Women’s Hospital,
during which he was given the Dunne Award for Humanism in Medicine
by Harvard Medical School. He subsequently completed a Dermatology
residency at Columbia University Medical Center, where he served
as a Chief Resident during his final year of training. After
residency, he completed a Melanoma Fellowship at Massachusetts
General Hospital/Harvard Medical School. He obtained his M.D. with
Alpha Omega Alpha honors from Rutgers–New Jersey Medical School.
Dr. Reddy is a board-certified dermatologist and maintains an
active clinical practice caring for patients at Massachusetts
General Hospital, where he also teaches and mentors medical
students and trainees.
Kevin Ryan
Board Advisor
Founder & CEO, AlleyCorp
Often called the “Godfather of NYC tech,” Kevin Ryan is one of the
leading internet entrepreneurs and investors in New York. He is a
co-founder of MongoDB, Business Insider, Gilt Groupe, Zola, Nomad
Health, Pearl Health, and Transcend Therapeutics, and founds and
actively invests in new companies with AlleyCorp every year. Kevin
currently serves on 10 company boards.
Earlier in his career, Kevin helped to grow DoubleClick first as
President and then as CEO, leading their growth from a 20-person
startup to a publicly-traded global leader with over 1,500
employees, through IPO in 1998, and acquisition by Google in 2007.
Kevin has been a civic leader in New York at the city and state
level. Appointed by Governor Cuomo, he served on a three-member
Fast Food Wage Board that successfully advocated for a wage
increase for the state’s fast food workers. Kevin was also a
member of the state’s Backend Expenses Commission, advising on
spending and enhancing efficiencies, as well as the MTA commission
focused on engaging startups and new technologies to improve
accessibility and congestion challenges in New York. Additionally,
Kevin served on the board of the Trust for Governors Island.
Kevin serves on the Board of Tech:NYC, where he is a founding
member and chairs the Policy Committee. He is also the Vice
Chairman of The Partnership for New York City, a Director Emeritus
at Human Rights Watch, and a member of the Council on Foreign
Relations. Previously, Kevin held positions on the boards of Yale
University, Yale University Press, INSEAD, Mercy Corps, The NYC
Investment Fund, the advisory board of Doctors Without Borders,
and the Yale International Council.
Actively engaged in philanthropy, Kevin and his wife Pascaline
Servan-Schreiber support organizations including University of the
People, The Marshall Project, MLT, Endeavor, Fund for Public
Health in NYC, and the Center for Mindful Learning. He continues
to be one of the leading funders of the Yale Program for
Psychedelic Science. AlleyCorp also invests out of a dedicated
Social Impact vertical, which funds both for-profit companies and
nonprofit entities dedicated to building technology solutions for
low-income and underserved families.
Kevin has been recognized as Entrepreneur of the Year by Ernst &
Young, LLP, featured as one of The 100 Most Influential New
Yorkers of the Past 25 Years by The Observer, and named one of the
50 Most Influential Business People by Crain’s New York Business,
where he was later inducted into the Hall of Fame.